Treatment of chronic hepatitis C in treatment-naïve patients

Ferreira, Marcelo Simão

doi:10.1590/s1413-86702007000700015

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the sample consisted of patients who used PEG-IFN, a higher percentage of patients with genotype 1 was expected. HCV genotype is an important parameter in the indication of treatment, given that genotype 1 presents lower rates of SVR compared with other genotypes, which is why patients with genotype 1 are treated for 48 weeks, while patients with other genotypes are treated for 24 weeks (Ferreira, 2007;Fried, Hadziyannis, 2004;Shepherd et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin

Rosa

Blatt

Peres

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

This study aimed to evaluate the rate of sustained virological response (SVR) and the clinical and treatment characteristics of patients with chronic hepatitis C (CHC). A retrospective uncontrolled cohort study was conducted among patients who received treatment for CHC between 2005 and 2008 attended at the Center for the Application and Monitoring of Injectable Medications, in Florianopolis, SC, Brazil. The inclusion criteria were: patients over 18 years of age, with a confirmed diagnosis of chronic hepatitis C according to Brazilian guidelines, treated with PEG-IFN alfa-2a or 2b associated with RBV. A total of 188 patients were included in the study: 70% men, 59% genotype 1, 27% coinfected with HIV, 31% with cirrhosis. The SVR rate, calculated by probability theory, was determined as 26% (max=57.4% and min=12.8%) and the intention to treat was 12.8%. Associations between Sustained Virological Response (SVR) and the variables sex (p=0.017), age (p=0.003), genotype (p=0.648) and cirrhosis (p=0.275), were determined in the bivariate analysis and only sex and age were significantly associated with SVR. The SVR rate was considered low, which can be partially explained by patients' unfavorable pretreatment characteristics.Uniterms: Hepatitis C. Hepatitis C Chronic. Effectiveness. Interferon alfa-2a. Interferon alfa-2b.O objetivo do estudo foi avaliar a taxa de resposta viral sustentada (RVS) e as características clínicas e do tratamento dos pacientes portadores de hepatite C crônica. Realizou-se uma coorte retrospectiva não controlada com recorte temporal dos anos de 2005 a 2008, dos pacientes atendidos no Polo de Aplicação e Monitoramento de Medicamentos Injetáveis, em Florianópolis, SC. Os critérios de inclusão foram: pacientes maiores de 18 anos, com diagnóstico confirmado de hepatite C crônica de acordo com o protocolo brasileiro, tratados com PEG-IFN alfa-2a ou 2b associado a ribavirina. Total de 188 pacientes foi incluído no estudo, 70% homens, 59% genótipo 1, 27% co-infectados com o HIV e 31% apresentando cirrose. A taxa de RVS calculada através da teoria das probabilidades foi de 26% (max=57,4% and min=12,8%) e por intenção de tratamento de 12,8%. Verificou-se a associação da RVS com as variáveis: sexo (p=0,017), idade (p=0,003), genótipo (p=0,648) e presença de cirrose (p=0,275). Somente sexo e idade foram associados significativamente com a RVS. A taxa de RVS foi considerada baixa e, em parte, pode ser explicada pelas características desfavoráveis dos pacientes para a obtenção de RVS.Unitermos: Hepatite C. Hepatite C Crônica. Efetividade. Interferona alfa-2a. Interferona alfa-2b.

show abstract

Section: Discussionmentioning

confidence: 99%

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin

Rosa

Blatt

Peres

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Usuários de drogas inalatórias ou intravenosas ilícitas, contágio vertical, contágio sexual, receptores de órgãos transplantados, também são vias de transmissão (Strauss, 2001;Indolfi et al, 2013;Prati, 2006). (Gallo et al, 2010;Rocca et al, 2004;Feld et al, 2010 (Ferreira, 2007;Czepiel et al, 2008;Georgel et al, 2010). (Mangia et al, 2010;Tanaka et al, 2010;Cannon et al, 2008;Pol et al, 2013).…”

Section: Transmissãounclassified

Influência dos polimorfismos do gene IL-28B na resposta à terapia com interferon peguilado e ribavirina em pacientes tratados por hepatite C crônica

Martins¹

View full text Add to dashboard Cite

Obstacles Facing Primary Health Care Physicians in Diagnosing and Managing Depressed Patients in the Tabuk Area of Saudi Arabia

Ahmad¹

2013

ME-JFM

View full text Add to dashboard Cite

Treatment of chronic hepatitis C in treatment-naïve patients

Cited by 3 publications

References 0 publications

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin

Influência dos polimorfismos do gene IL-28B na resposta à terapia com interferon peguilado e ribavirina em pacientes tratados por hepatite C crônica

Obstacles Facing Primary Health Care Physicians in Diagnosing and Managing Depressed Patients in the Tabuk Area of Saudi Arabia

Contact Info

Product

Resources

About